Last update 25 May 2025

MG-01

Overview

Basic Info

Drug Type
Chemical drugs
Synonyms
MG-01
Target-
Action-
Mechanism-
Therapeutic Areas
Immune System DiseasesInfectious DiseasesOtorhinolaryngologic Diseases+ [1]
Active Indication
Allergic asthmaRhinitis, AllergicRhinoconjunctivitis
Inactive Indication
House dust mite allergyRhinitis, Allergic, PerennialRhinitis, Allergic, Seasonal
Originator Organization
Inmunotek SLInmunotek SL
Active Organization
Inmunotek SLInmunotek SL
Inactive Organization-
License Organization-
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Related

3
Clinical Trials associated with MG-01
NCT04891237
/ RecruitingPhase 3
A Randomized, Double-Blinded, Placebo-Controlled, Prospective, Multicenter CT to Evaluate Efficacy and Safety of Subcutaneous Immunotherapy in Subjects With Rhinitis With/Without Mild to Moderate Asthma Sensitized to Olive and Grass Pollen
NCT04898283
/ RecruitingPhase 3
Prospective, Multicentre, Doubleblind, Placebo-controlled RCT to Evaluate Efficacy and Safety With SC Immunotherapy in Patients With Rhinitis/Rhinoconjunctivitis With or Without Mild to Moderate Asthma Sensitised to Grasses and Cupressaceae
NCT04874714
/ TerminatedPhase 3
Prospective, Randomized, Placebo-controlled, Multi-center Trial Comparing the Efficacy and Safety of Subcutaneous Immunotherapy With a Mixture of Grasses and Mites at Adequate Doses Versus Monotherapy, for the Treatment of Allergy
100 Clinical Results associated with MG-01
Login to view more data
100 Translational Medicine associated with MG-01
Login to view more data
100 Patents (Medical) associated with MG-01
Login to view more data
100 Deals associated with MG-01
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Allergic asthmaPhase 3
Spain
Inmunotek SLInmunotek SL
31 May 2021
Rhinitis, AllergicPhase 3
Spain
Inmunotek SLInmunotek SL
31 May 2021
House dust mite allergyPhase 3
Spain
Inmunotek SLInmunotek SL
30 Apr 2021
Rhinitis, Allergic, PerennialPhase 3
Spain
Inmunotek SLInmunotek SL
30 Apr 2021
Rhinitis, Allergic, SeasonalPhase 3
Spain
Inmunotek SLInmunotek SL
30 Apr 2021
RhinoconjunctivitisPhase 3
Spain
Inmunotek SLInmunotek SL
30 Apr 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free